Cell line · CVCL_8607
92-1 [Human uveal melanoma]
Cancer cell line, Homo sapiens. Uveal melanoma. 41 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. 92-1 [Human uveal melanoma]. Cell lines, record CVCL_8607. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_8607
On this page
Cell line
As Cellosaurus gives it.
- Name
- 92-1 [Human uveal melanoma]
- Accession
- CVCL_8607
- RRID
- RRID:CVCL_8607
- Synonyms
- 92_1, 92.1, 921
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 76Y
- Category
- Cancer cell line
- Diseases
- Uveal melanoma (NCIt C7712)
- Derived from
- Eye, uvea (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2026-10-22
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers41
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Combination of Three Herbal Components (ISL, Que, Meth) Suppresses Uveal Melanoma Growth via Gαq/MEK/YAP Axis Modulation and Apoptosis. | Biomedicines | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical response of uveal melanomas to the velcrin compound, BAY 2666605. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| GDF15 Reprograms the Microenvironment to Drive Liver Metastasis of Uveal Melanoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Network-based analysis reveals potential microRNA regulation of oncogenic pathways in SOX10-depleted uveal melanoma. | Cell Mol Life Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A CRISPR-Cas13d cancer therapeutic enables selective elimination of uveal melanoma. | Mol Ther Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| UC2288 decreases the viability and metastatic activity of human Uveal melanoma cells via activating the AMPK/eIF2/ATF4 ER stress axis. | Eur J Pharmacol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Discovery of α-Adrenoceptor Antagonists as a Potential New Treatment Option for Uveal Melanoma. | Biomolecules | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR-Cas13d-Mediated Targeting of a Context-Specific Essential Gene Enables Selective Elimination of Uveal Melanoma. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Allele-specific depletion of GNAQ Q209L via siRNA or an rAAV2-shRNA vector induces selective toxicity in GNAQ Q209L uveal melanoma cells. | Mol Ther Oncol | 2025 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 41
See all 41 papersRelatives3
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | 92.1-A | CVCL_C4PP | Cell lines | |
| Derived from it | 92.1-B | CVCL_C4PQ | Cell lines | |
| From the same person | 92-2 [Human uveal melanoma] | CVCL_C300 | Cell lines |
Cell banks2
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_8607
GET https://conductscience.org/api/cell-lines/v1/CVCL_8607/papers?page=2